The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, e.g. which are mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.
The invention provides a method of treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.
US7235581B2
申请人:——
公开号:US7235581B2
公开(公告)日:2007-06-26
[EN] 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES<br/>[FR] DERIVES DE 4-PYRROLIDINO-PHENYL-BENZYL ETHER
申请人:HOFFMANN LA ROCHE
公开号:WO2004026826A1
公开(公告)日:2004-04-01
Racemic or enantiomerically pure 4-pyrrolidino derivatives of formula (I), processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, e.g. which are mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.